TransCode Therapeutics (RNAZ) said Friday that it will implement a 1-for-28 reverse stock split to increase its per-share price in order to satisfy Nasdaq's minimum bid price requirement.
The planned reverse split will reduce the number of the company's outstanding shares to approximately 833,620 shares from 23.3 million shares.
The effective date of the reverse stock split has not yet been determined, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.